Louis Maes - Concepedia

Author

Louis Maes

Also Known As

L MAES, L Maes, L. MAES, L. Maes, LOUIS MAES, Lou Anne Maes, Louis J. Maes, Louis J. R. Maes, Louis J.R.M. Maes, Louis MAES

440

Publications

15K

Citations

H-Index

152

Concepts

All Affiliations

University of Antwerp Ghent University Instituut voor Tropische Geneeskunde Centre National de la Recherche Scientifique Drugs for Neglected Diseases Initiative

About

Louis Maes is an author at University of Antwerp specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	128	6.3K
2	Natural Sciences	29	51	3.1K
3	Health Sciences	11	11	343
4	Engineering	7	7	347
5	Education	3	3	62

Louis Maes

269

Publications

11.8K

Citations

H-Index

Page 1

	Year	Citations
Quorum Sensing Inhibitors Increase the Susceptibility of Bacterial Biofilms to Antibiotics In Vitro and In Vivo Gilles Brackman, Paul Cos, Louis Maes, Antimicrobial Agents and Chemotherapy	2011	541
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Wesley C. Van Voorhis, John H. Adams, Roberto Adelfio, PLoS Pathogens Drug TargetBioorganic ChemistryAntiparasitic AgentMalariaMedicinal Chemistry	2016	441
Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP) Koen Jansen, Leen Heirbaut, Robert Verkerk, Journal of Medicinal Chemistry Structure–activity RelationshipDrug TargetCellular PharmacologyPharmacotherapyChemical Biology	2014	264
Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold Koen Jansen, Leen Heirbaut, Jonathan D. Cheng, ACS Medicinal Chemistry Letters Bioorganic ChemistrySelective InhibitorsChemical BiologyPharmaceutical ChemistryMedicinal Chemistry	2013	246
In Vitro Susceptibilities of <i>Leishmania donovani</i> Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences M Vermeersch, Raquel Inocêncio da Luz, K. Toté, Antimicrobial Agents and Chemotherapy Sodium StibogluconateBiochemistryDifferential Susceptibility DeterminesMedicineAntiparasitic Agent	2009	227
Advancing Drug Innovation for Neglected Diseases—Criteria for Lead Progression Solomon Nwaka, Bernadette Ramirez, Reto Brun, PLoS neglected tropical diseases Drug TargetPharmaceutical InnovationDrug ResistanceTranslational MedicineMedicinal Chemistry	2009	193
Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent Hideo Imamura, Tim Downing, Frederik Van den Broeck, eLife GeneticsGenomicsVisceral LeishmaniasisParasite GenomicsDrug Resistance	2016	187
Discovery of Novel, Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy Lars Devisscher, Samya Van Coillie, Sam Hofmans, Journal of Medicinal Chemistry Lipid PeroxidationPharmacotherapyDrug-like Ferroptosis InhibitorsChemical BiologyRedox Biology	2018	160
PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome H. Van de Ven, Caroline Paulussen, Pim‐Bart Feijens, Journal of Controlled Release NanomedicineAntifungal AgentEngineeringVivo AlternativesMedicine	2012	156
Inhibitory Effect of Biocides on the Viable Masses and Matrices of <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> Biofilms K. Toté, Tessa Horemans, Dirk Vanden Berghe, Applied and Environmental Microbiology	2010	155

Page 1